ETENDERS

Contract award notice

Information

Published

Date of dispatch of this notice: 28/11/2017

External Reference: 2017-228620

TED Reference: 2017/S 230-479224

Contract award notice

[NoticeContractAward]

[NoticeContractAwardSub]

[Directive201424]

[Section1]: [Ca]

I.1)

[NameAddressContact]

Health Service Executive (HSE)
N/A
Head Office
Naas
Millennium Park
IE
[Contactpoint]: Sabrina Byrne
[AddressEmail]: sabrina.byrne@hse.ie
[Nutscode]:  IE -  IRELAND
[Internets]:
[UrlGeneral]: http://www.hse.ie
[UrlBuyerprofile]: https://irl.eu-supply.com/ctm/Company/CompanyInformation/Index/461

I.2)

[JointProcurement]

[JointProcurementCentral]
I.4)

[CaType]

[MaintypePublicbody]
I.5)

[Mainactivity]

[MainactivHealth]

[Section2]: [Object]

II.1)

[QuantityScopeContract]

II.1.1)

[TitleContract]

National Contract for Directly Acting Antiviral Medicines for GT3 Treatment in Hep C Programme
[Fileref]:  9464
II.1.2)

[CpvMain]

33600000  - 
II.1.3)

[TypeContract]

[Supplies]
II.1.4)

[DescrShort]

Contract for Directly Acting Antiviral Medicines for GT3 Treatment in Hep C Programme
II.1.6)

[LotsInfo]

[DivisionLots]: [No]
II.1.7)

[ValueTotal]

[ValueExclVat]:  2856000.00  EUR
II.2)

[Description]

II.2.2)

[CpvAdditional]

33600000  - 
II.2.3)

[PlacePerformance]

[Nutscode]:  IE -  IRELAND
[MainsiteplaceWorksDelivery]:  
Ireland
II.2.4)

[DescrProcurement]

The HSE wishes to establish a national contract for the provision of Directly Acting Antiviral (DAAs) medicines for use in provision of treatment to a limited number of GT3 patients to the end of 2017.
II.2.5)

[AwardCriteria]

[AwardCriteriaBelow]
[AwardCriterionQuality]  -  [AwardCriterionName]:  Quality  /  [Weighting]:  10%
[AwardCriterionQuality]  -  [AwardCriterionName]:  Contract Management  /  [Weighting]:  10%
[AwardLowestCost]  -  [AwardCriterionName]:  Cost  /  [Weighting]:  80%
II.2.11)

[OptionsInfo]

[Options]: [No]
II.2.13)

[EuProgrInfo]

[EuProgrRelated]: [No]
II.2.14)

[InfoAdditional]

The stated contract value is based on the highest tendered option received.

[Section4]: [Procedure]

IV.1)

[Description]

IV.1.1)

[TypeProcedure]

[ProctypeOpen]
[ProctypeAccelerated]
[Justification]:  
The accelerated procedure is justified as clinicians have identified a number of patients in urgent need of treatment using the GT3 regimen and the remaining budget available to the National Hepatitis C Treatment Programme for 2017 will allow limited access under existing commercial terms and reduce significantly the numbers of patients overall that can be treated.
IV.1.8)

[GpaInfo]

[GpaCovered] : [Yes]
IV.2)

[InfoAdmin]

IV.2.1)

[PubPrevious]

[NumberOj]: 2017/S 190-388547

[Section5]: [AwardOfContract]

[ContractNumber]: 1

[TitleContract]: National Contract for Direct Acting Antiviral Medicines for GT3 Treatment in Hep C Programme

[AwardConfirm]: [Yes]
V.2)

[AwardOfContract]

V.2.1)

[DateAward]

01/11/2017
V.2.2)

[AwardOffersInfo]

[OffersReceived]:  7
[AwardedGroup] :  [Yes]
V.2.3)

[AwardedToName]

Gilead Sciences Ireland UC
259755
Ida Business & Technology Park
Carrigtohill
IE
[Nutscode]:  IE -  IRELAND

[AwardedSme] : [No]
Abbvie Limited
510846
14 Riverwalk, Citywest Business Campus
Dublin
IE
[Nutscode]:  IE -  IRELAND

[AwardedSme] : [No]
V.2.4)

[ValueContractInfo] ([ExclVat])

[ValueEstimTotalContract]:  3400000.00  EUR
[ValueTotalFinal]:  2856000.00  EUR

[Section6]: [InfoComplement]

VI.4)

[AppealsProcedure]

VI.4.1)

[AppealsBody]

The High Court
Four Courts
Dublin 7
IE